Cost‐effectiveness of the diabetes remission clinical trial ( DiRECT )/Counterweight‐Plus weight management programme, based on 5‐year follow‐up
Diabetic Medicine · 2026-06 · 43 (6)
DOI: 10.1111/dme.70306 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetic Medicine, online erschienen am 29.03.2026. Verfasst von A Davies und 8 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics and Health Technology Assessment, School of Health and Wellbeing, College of Medical, Veterinary & Life Sciences, University of Glas…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Weight Reduction Programs, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Diabetes UK.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Follow‐up of the Counterweight‐Plus intervention in DiRECT has demonstrated 6.1 kg weight loss and 10 % remissions from type 2 diabetes at 5 years. We previously reported cost‐effectiveness based on 2‐year results. We now present an updated cost‐effectiveness analysis, based on available 5‐year data.
Methods
A lifetime cost‐effectiveness analysis was conducted using the 5‐year data from DiRECT, including time to relapse from remission from type 2 diabetes, intervention costs (practitioner appointment visits, low‐energy formula diet sachets), routine healthcare resource use (primary, secondary, and tertiary care contacts), medications (anti‐hypertensive and anti‐diabetic medicines), and quality of life (EuroQol EQ‐5D‐3L). Modelling assumed that all those in remission at 5 years would relapse after a maximum of 10 years.
Results
Total (discounted) healthcare cost‐savings (excluding intervention costs) per participant over 5 years amounted to £2091. On average, healthcare costs per annum were ~£480 per participant lower in the intervention arm ( p < 0.05). Intervention resource use beyond 2 years added relatively little to the total intervention cost (set‐up, formula diet and practice visits), which amounted to £1691 (95% CI: £1566, 1822) per participant over 5 years. Reduced hospital admissions accounted for the major part of this saving, with the remainder being across primary and secondary care, and anti‐diabetic and anti‐hypertensive medications. Remission in DiRECT was associated with a significant improvement in quality of life, and the intervention arm was modelled to achieve both cost‐savings of ~£400 and quality adjusted life year gains of 0.043 over 5 years, with further benefits due to reduced mortality in remission. Over the full lifetime horizon of the analysis the intervention was modelled to produce 0.08 incremental QALYs, saving £496 per participant.
Conclusions
The costs involved in achieving remissions from type 2 diabetes with the Counterweight‐Plus diet programme were offset within 5 years through reduced healthcare resource use. Though remission may ultimately relapse, sustained weight loss brings other longer term health gains. The intervention, even using one‐to‐one face‐to‐face contacts rather than remote delivery, which is increasingly adopted, generated both health gains and cost‐savings compared with current best practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Economics and Health Technology Assessment, School of Health and Wellbeing, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
- Human Nutrition, School of Medicine, Dentistry & Nursing, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
- Robertson Centre for Biostatistics, School of Health and Wellbeing, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
- School of Cardiovascular and Metabolic Health, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
- Newcastle Magnetic Resonance Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
ORCID-Profile: E Grieve, N Sattar, M E J Lean
Förderung
- Diabetes UK
Zitieren
APA
Davies, A., Grieve, E., McCombie, L., McIntosh, A., McConnachie, A., Leslie, W. S., Sattar, N., Taylor, R., & Lean, M. E. J. (2026). Cost‐effectiveness of the diabetes remission clinical trial ( DiRECT )/Counterweight‐Plus weight management programme, based on 5‐year follow‐up. Diabetic Medicine, 43(6). https://doi.org/10.1111/dme.70306
Vancouver
Davies A, Grieve E, McCombie L, McIntosh A, McConnachie A, Leslie WS, et al. Cost‐effectiveness of the diabetes remission clinical trial ( DiRECT )/Counterweight‐Plus weight management programme, based on 5‐year follow‐up. Diabetic Medicine. 2026;43(6). doi:10.1111/dme.70306
BibTeX
@article{Davies2026,
author = {Davies, A and Grieve, E and McCombie, L and McIntosh, A and McConnachie, A and Leslie, W S and Sattar, N and Taylor, R and Lean, M E J},
title = {Cost‐effectiveness of the diabetes remission clinical trial ( DiRECT )/Counterweight‐Plus weight management programme, based on 5‐year follow‐up},
journal = {Diabetic Medicine},
year = {2026},
volume = {43},
number = {6},
doi = {10.1111/dme.70306}
}
EUVIMED